Kuan-Lin Huang | Mount Sinai

Biography

Research Topics

Alzheimer's Disease, Bioinformatics, Biomedical Informatics, Brain, Cancer, Cancer Genetics, Computational Biology, Epidemiology, Epigenomics, Gene editing, Genomics, Mass Spectrometry, Mathematical and Computational Biology, Neural Networks, Neurology, Personalized Medicine, Pharmacogenomics, Phosphorylation, Post-Transcriptional Processing, Protein Structure/Function, Proteomics, Systems Biology, Translation

Multi-Disciplinary Training Area

Artificial Intelligence and Emerging Technologies in Medicine [AIET], Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS], Neuroscience [NEU]

Education

BA, Wesleyan University

PhD, Washington University in St. Louis

Postdoc, Washington University in St. Louis

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Huang during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Founder/Co-Founder/Partner

Open Box Science

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Huang during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Founder/Co-Founder/Partner

Open Box Science

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.